

CURRICULUM VITAE

Francesca Ceccherini-Silberstein

Born in Rome on 1969-05-14

e-mail: ceccherini@med.uniroma2.it

Actual Position

Associate Professor at the Chair of Virology, Department of Experimental Medicine, University of Rome Tor Vergata, Rome Italy

Scientific Director and Vice-president of the Italian Foundation of HCV Virology Italian Resistance Network Study Group – Fondazione VIRONET C

Published 215 full papers in prestigious journals, with a median impact factor of 4.82; H index of 36 (by Google Scholar), total N° of citations: 3924 (by Google Scholar)

Attended at numerous National and International Conferences presenting her work, with more than 80 Invited Lectures, 200 Oral Presentations, and 150 Posters

Education

2001: PhD in Biology (Magna cum Laude) at the University of Munich Ludwig-Maximilians, Munich, Germany

1994: Degree with honours (110/110 cum Laude) in Pharmaceutical Chemistry and Technology at the University of Rome La Sapienza

Academic and Research Activity

2016-today: Qualified as a Full Professor in the s.s.d MED/07 Microbiology and Clinical Microbiology

2014-today: Associate Professor confirmed at the Chair of Virology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata

2008-2014: Assistant Professor, at the Chair of Virology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Confirmed on 1/10/2011

2005-2011: Professor of Virology at the Science Faculty, University of L'Aquila

2006-2007: Professor of Microbiology and Clinical Microbiology at the Science Faculty, University of L'Aquila

2003-2007: Senior Scientist at the Chair of Virology, Department of Experimental Medicine, University of Rome Tor Vergata

2002-2003: Postdoctoral Fellow at the Chair of Virology, Department of Experimental Medicine, University of Rome Tor Vergata

2000-2002: Research Fellow at the Chair of Virology, Department of Experimental Medicine, University of Rome Tor Vergata, with a grant (AIDS-program) by the Italian National Institute of Health, Rome

1996-1999: PhD student working at the Institute for Molecular Virology, GSF-National Research Center for Environment and Health, Munich, Germany

1997-1998: Annual International Fellowship from the University of Rome La Sapienza

1994-1996: Full-time research assistant in the Laboratory of Organ and System Pathophysiology, Italian National Institute of Health, Rome

1991-1994: Guest student in the Laboratory of Organ and System Pathophysiology, Italian National Institute of Health, Rome

Her research interests and expertise are on viruses since 1996. Main interests: on HIV infection, antiviral drugs and strategies, HIV-HBV-HCV drug-resistance, viral pathogenesis, viral tropism, viral evolution and dynamics, genotypic (by Sanger and NGS sequencing), structural and functional analysis of viral proteins

She cooperates with many nationally and internationally recognized scientific researchers through several grants from the Italian National Institute of Health, Italian Ministry of Health, the Ministry of University and Scientific Research, Italian Medicines Agency, the European Community and Industrial Companies

Research coordination

2018-today: Leader of Research Unit for the study “Development of an Italian clinical/diagnostic network focused on the prevention and management of virologic failures in hepatitis C virus (HCV) patients treated with direct antiviral agents (DAAs)”. Progetto di Ricerca Finalizzata, financed by the Italian Ministry of Health: RF-2016-02362422

2017-today: Project Leader of the study “Valutazione dell’impatto della quantità di HIV-DNA e resistenza archiviata sull’outcome virologico di pazienti che cambiano terapia nel contesto di ottimizzazione della terapia antiretrovirale in real life” financed by Gilead Fellowship Program 2017

2017-today: Leader of Research Unit for the study “Impact on bone mineral density (BMD) of Tenofovir-sparing antiretroviral regimens in HIV-positive menopausal women affected by osteopenia: the Tenofovir Sparing Strategy (TESS) study”. Project financed by AIFA, Prot. FARM12FEXH.

2016-2018: Project Leader of the Study entitled “HCV variability and resistance in HCV mono and HIV/HCV co-infected patients: efficacy of DAA treatment across different genotypes”, financed by Merck Sharp and Dhome

2013-2017: Leader of Research Unit for the study “Studio dei determinanti di resistenza secondaria e primaria di HIV-1 ai farmaci antiretrovirali per il controllo della trasmissione a livello di popolazione” from the Italian Ministry of University and Scientific Research, PRIN Protocollo: 2012L783TW

2012-today: Leader of Research Unit “Omics application in the virologic area” from the Italian Ministry of University and Scientific Research. Progetto di Ricerca Bandiera InterOmics Protocollo PB05 1°

2011-2013: Project Leader of the Study entitled “Characterization of the HCV-NS3 protease variability among different HCV-genotypes in terms of genetic barriers in the generation of resistance mutations to protease inhibitors in advanced clinical development”, financed by Merck Sharp and Dhome

2009-2014: Leader of Research Unit for CHAIN, the Collaborative HIV and Anti-HIV Drug Resistance Network, funded by the European Commission Framework 7 Program. Integrated Project no. 223131

2006-2008: Leader of Research Unit for VI Programma Nazionale di Ricerca sull’AIDS 2006, del Progetto “Le resistenze ai farmaci anti-HIV: metodologie diagnostiche innovative e impatto clinico”. Convenzione n. 30G.47

Special Assignments

2017-today: Scientific Director and Vice-president of the Italian Foundation of HCV Virology Italian Resistance Network Study Group – Fondazione VIRONET C

2017-today: Member of Data and Safety Monitoring Board (DSMB) for the ANRS 170 QUATUOR trial “Essai multicentrique, en ouvert, randomisé en 2 groupes parallèles, évaluant la non-infériorité d’un traitement de maintenance à 4 jours consécutifs sur 7 versus la poursuite du traitement antirétroviral en continu, chez des patients en succès thérapeutique sous ARV”

2012-2017: Member of Data and Safety Monitoring Board (DSMB) for the ANRS 146 OPTIMAL trial “Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts below 200 cells/mm³”

2014-2016: Member of the Coordinator and Scientific Comity of the Italian Association of Liver Study (AISF)

2013-today: Member of the World Health Organization Surveillance Drug Resistance Mutations Working Group

2013-today: Member of the Editorial board in PLoS ONE and AIDS Reviews

2013-today: Member of the Faculty at The advanced training in the clinical interpretation of drug resistance testing results, Catholic University of Leuven, Belgium

2012-today: Member of the Faculty at the Residential Course on Clinical Pharmacology of Antiretrovirals, University of Torino

2012-today: Member of the Secretary Committee of the Italian Cohort of Antiretroviral-Naïve Patients (ICONA Foundation)

2010-today: Member of the European HIV Drug Resistance Guidelines Panel

2010-today: Member of the Scientific Organization Secretary of ICAR, Italian Conference on AIDS and Retroviruses; and in the Scientific Organization Committee of the European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance

2006-today: Member of the Scientific Committee of the Italian Cohort of Antiretroviral-Naïve Patients (ICONA Foundation)

2006-today: Reviewer for peer reviewed journals (as *J Clin Microbiol*, *Clin Microbiol Infect*, *J Ant Chem*, *Antiv Ther*, *J Infect Dis*, *AIDS Rev*, *Retrovirol*, *Eur J Clin Micr & Infect Dis.*, *PLoS Path*, *HIV Med*, *PLoS ONE*, *J of Virol*, *J of hepatology*). Median of revised articles / year = 30

Awards:

Research Winner of the Gilead Fellowship Program 2017

G.B. Rossi 2008 prize for the best publication in the HIV-field in 2007-2008 (Ceccherini Silberstein et al, *J Virol*. 2007. 81:11507-11519)

G.B. Rossi 2009 prize for the best publication in the HIV-field in 2008-2009 (Ceccherini Silberstein = Last name, Svicher et al., *Antimicrob Agents Chemother*. 53:2816-23, 2009)

Readfiles 2008 prize for the best publication in the HIV-field in 2007-2008 (Ceccherini Silberstein = coauthor, Svicher et al., *J Infect Dis*. 15:1408-1418, 2008)

Roma 2 Novembre 2018

Francesca Ceccherini-Silberstein
